Quince Therapeutics Stock Extends Rally On Strategic Review

Benzinga02-12

Quince Therapeutics Inc (NASDAQ:QNCX) shares are soaring again on Wednesday as the company has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value. Here’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610968220?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/11/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-02-12 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610968220","market":"us","top_or_hot":-1,"title":"Quince Therapeutics Stock Extends Rally On Strategic Review","media":"Benzinga","content":"<div>\n<p>Quince Therapeutics Inc (NASDAQ:QNCX) shares are soaring again on Wednesday as the company has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value. Here’s ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quince Therapeutics Stock Extends Rally On Strategic Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuince Therapeutics Stock Extends Rally On Strategic Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 02:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quince Therapeutics Inc (NASDAQ:QNCX) shares are soaring again on Wednesday as the company has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value. Here’s ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review","article_id":"2610968220","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/11/Defense--Biotech-Favored.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50555353/quince-therapeutics-stock-extends-rally-on-strategic-review","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610968220","pubTimestamp":1770836340,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Quince Therapeutics is soaring again on Wednesday as the company has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","QNCX":"Quince Therapeutics, Inc.","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","BK4217":"自存仓储房地产信托","SMA":"Smartstop Self Storage REIT Inc"},"translate_title":"Quince Therapeutics股票因战略审查而延续涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"QNCX":1,"LENZ":1.5},"content_text":"Quince Therapeutics Inc (NASDAQ:QNCX) shares are soaring again on Wednesday as the company has engaged LifeSci Capital to explore strategic alternatives aimed at maximizing shareholder value. Here’s what investors need to know.\nQuince Therapeutics this week announced that it has engaged LifeSci Capital as its exclusive financial advisor to explore various strategic options, including potential partnerships and restructuring of the company’s liabilities.\nThis strategic move has continued to spur the stock’s price surge Wednesday afternoon, with shares experiencing a dramatic increase in trading volume, exceeding 675 million shares versus an average of 28 million.\nThe company, which focuses on therapies for rare diseases, is considering options such as mergers, acquisitions and licensing deals to enhance its market position.\nWhile the company cautioned that there is no guarantee of a specific deal resulting from this review, the market is reacting positively, betting on the potential for a sale or partnership that could unlock shareholder value.\nCurrently, Quince Therapeutics is trading 51.1% below its 20-day simple moving average (SMA) and 68.2% below its 50-day SMA, indicating a significant distance from these key moving averages. Over the past 12 months, shares have decreased by 35.78%, and they are currently positioned closer to their 52-week lows than highs, which reflects ongoing challenges for the stock.\nThe RSI is at 31.15, indicating neutral territory, while the MACD is below its signal line, suggesting bearish pressure on the stock. The combination of neutral RSI and bearish MACD indicates mixed momentum, reflecting the stock’s current volatility and uncertainty.\nQuince Therapeutics is a preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company has developed a broad bone-targeting drug platform designed to deliver small molecules, peptides or large molecules directly to the site of bone fracture and disease, promoting rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.\nThis strategic engagement with LifeSci Capital is crucial as the company looks to explore partnerships and joint ventures that could enhance its market position and address its current challenges. The potential for restructuring and partnerships could significantly impact the company’s trajectory, making it a stock to watch in the biotech sector.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $8.71. Recent analyst moves include:\nQNCX Price Action: Quince Therapeutics shares were up 47.38% at 77 cents at the time of publication on Wednesday, according to Benzinga Pro data.\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610968220","isCrawlerRequest":true}